{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:03:41Z","timestamp":1786601021007,"version":"build-2736575974"},"reference-count":237,"publisher":"Tech Science Press","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.066624","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T08:57:13Z","timestamp":1757062633000},"page":"2787-2831","source":"Crossref","is-referenced-by-count":8,"title":["Nanotechnology-Driven Treatment Strategies for Breast Cancer: Recent Advances and Innovations"],"prefix":"10.32604","volume":"33","author":[{"given":"Neha","family":"Raina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahika","family":"Kanojia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avril","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshav Raj","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardeep Singh","family":"Tuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. T. M. Mijanur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vetriselvan","family":"Subramaniyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2024.0510","article-title":"The treatment of breast cancer in the era of precision medicine","volume":"22","author":"Bai","year":"2025","journal-title":"Cancer Biol Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1021\/nn507433p","volume":"9","author":"Qiao","year":"2015","journal-title":"ACS Nano"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5306\/wjco.v13.i3.209","article-title":"Breast cancer in India: present scenario and the challenges ahead","volume":"13","author":"Mehrotra","year":"2022","journal-title":"World J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/1097-0142(196005\/06)13:3<559::AID-CNCR2820130322>3.0.CO;2-0","article-title":"A study of the epidemiology of cancer of the breast","volume":"13","author":"Wynder","year":"1960","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/iub.2764","article-title":"Recent advances in BCRP-induced breast cancer resistance treatment with marine-based natural products","volume":"75","author":"Kanoujia","year":"2023","journal-title":"IUBMB Life"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"ref8","unstructured":"Breast Cancer Statistics. How common is breast cancer? American Cancer Society [Internet]. [cited 2025 May 23]. Available from: https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/about\/how-common-is-breast-cancer.html."},{"key":"ref9","first-page":"229","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clin"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.18632\/aging.202502","article-title":"Global incidence and mortality of breast cancer: a trend analysis","volume":"13","author":"Huang","year":"2021","journal-title":"Aging"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40659-017-0140-9","article-title":"Awareness and current knowledge of breast cancer","volume":"50","author":"Akram","year":"2017","journal-title":"Biol Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10549-017-4367-5","article-title":"Predictive factors on outcomes in metaplastic breast cancer","volume":"165","author":"Leyrer","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.nano.2017.03.003","article-title":"Natural lipids enriched self-nano-emulsifying systems for effective co-delivery of tamoxifen and naringenin: systematic approach for improved breast cancer therapeutics","volume":"13","author":"Sandhu","year":"2017","journal-title":"Nanomed"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"106535","DOI":"10.1016\/j.intimp.2020.106535","article-title":"Breast cancer: biology, biomarkers, and treatments","volume":"84","author":"Barzaman","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molonc.2010.04.004","article-title":"Histological types of breast cancer: how special are they?","volume":"4","author":"Weigelt","year":"2010","journal-title":"Mol Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4137\/CPath.S31563","article-title":"Diversity of breast carcinoma: histological subtypes and clinical relevance","volume":"8","author":"Makki","year":"2015","journal-title":"Clin Med Insights Pathol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ctrv.2011.11.005","article-title":"Molecular biology in breast cancer: intrinsic subtypes and signaling pathways","volume":"38","author":"Eroles","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-014-3056-x","article-title":"Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status","volume":"147","author":"Prat","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1200\/JCO.2014.56.6232","article-title":"Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age \u226550 years: evidence from an individual patient data meta-analysis","volume":"33","author":"Phi","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref21","first-page":"e2300666","article-title":"Special issue: nanotherapeutics in women\u2019s health emerging nanotechnologies for triple-negative breast cancer treatment","volume":"20","author":"Torres Quintas","year":"2024","journal-title":"Small"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"105890","DOI":"10.1016\/j.ejps.2021.105890","article-title":"Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer","volume":"164","author":"Dubey","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ncrna10010014","article-title":"MicroRNA-204 regulates angiogenesis and vasculogenic mimicry in CD44+\/CD24\u2212 breast cancer stem-like cells","volume":"10","author":"Resendiz-Hern\u00e1ndez","year":"2024","journal-title":"Non-coding RNA"},{"key":"ref24","unstructured":"Saad Abed A, Saad Abed Karkosh I, Saad Abed Karkosh Z. Molecular and physiological facts affected breast cancer development [Internet]. [cited 2025 Jun 1]. Available from: https:\/\/wahj-dna.com.iq\/en\/molecular-and-physiological-facts-affected-breast-cancer-development\/."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fonc.2020.00069","article-title":"The CaSR in pathogenesis of breast cancer: a new target for early stage bone metastases","volume":"10","author":"Das","year":"2020","journal-title":"Front Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1517\/14728222.2011.650632","article-title":"The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies","volume":"16","author":"Corsini","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5306\/wjco.v5.i3.283","article-title":"Pathogenesis, prevention, diagnosis and treatment of breast cancer","volume":"5","author":"Shah","year":"2014","journal-title":"World J Clin Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acc.2015.05.001","article-title":"Biomarkers in breast cancer: where are we and where are we going?","volume":"71","author":"Duffy","year":"2015","journal-title":"Adv Clin Chem"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e12822","DOI":"10.1111\/cpr.12822","article-title":"A review on methods for diagnosis of breast cancer cells and tissues","volume":"53","author":"He","year":"2020","journal-title":"Cell Prolif"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"9083","DOI":"10.1007\/s13277-015-3661-2","article-title":"Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer?","volume":"36","author":"Burrai","year":"2015","journal-title":"Tumor Biol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bbcan.2011.01.001","article-title":"Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy","volume":"1815","author":"Mukhopadhyay","year":"2011","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref32","unstructured":"Limaiem F, Ahmad F. Mucinous breast carcinoma. StatPearls [Internet]. [cited 2025 Jun 1]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538334\/."},{"key":"ref33","first-page":"e31860","article-title":"Dosimetric study comparing 3D conformal radiotherapy (3D-CRT), intensity modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) in hypofractionated one-week radiotherapy regimen in breast cancer","volume":"14","author":"Ahmad","year":"2022","journal-title":"Cureus"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/jpm14070723","article-title":"Emerging applications of nanoparticles in the diagnosis and treatment of breast cancer","volume":"14","author":"Oehler","year":"2024","journal-title":"J Pers Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/cncr.29903","article-title":"Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation status","volume":"122","author":"Shah","year":"2016","journal-title":"Cancer"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41568-020-0266-x","article-title":"Key steps for effective breast cancer prevention","volume":"20","author":"Britt","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(96)90010-0","article-title":"Prospective assessment of breast-feeding and breast cancer incidence among 89 887 women","volume":"347","author":"Michels","year":"1996","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-3-030-20301-6_2","article-title":"Epidemiology of breast cancer in women","volume":"1152","author":"Coughlin","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/sj.bjc.6690235","article-title":"Characteristics of small breast and\/or ovarian cancer families with germline mutations in BRCA1 and BRCA2","volume":"79","author":"Ligtenberg","year":"1999","journal-title":"Br J Cancer"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequenc-ing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"New Engl J Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/jnci\/92.14.1126","article-title":"Genetic and hormonal risk factors in breast cancer","volume":"92","author":"Martin","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199206183262501","article-title":"Breast augmentation: a risk factor for breast cancer?","volume":"326","author":"Berkel","year":"1992","journal-title":"New Engl J Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"e0302143","DOI":"10.1371\/journal.pone.0302143","article-title":"Determinants of early initiation of breastfeeding following birth in West Africa: a multilevel analysis using data from multicountry national health surveys","volume":"19","author":"Terefe","year":"2024","journal-title":"PLoS One"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1055-9965.EPI-06-0034","article-title":"Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis","volume":"15","author":"McCormack","year":"2006","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"ref45","first-page":"139","author":"Abbas","year":"2018","journal-title":"Neoplasm"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/jcp.46.2.189-b","article-title":"Method for grading breast cancer","volume":"46","author":"Elston","year":"1993","journal-title":"J Clin Pathol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3390\/jpm11080808","article-title":"Breast cancer treatments: updates and new challenges","volume":"11","author":"Burguin","year":"2021","journal-title":"J Pers Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jconrel.2020.07.003","article-title":"A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer","volume":"326","author":"Jain","year":"2020","journal-title":"J Control Release"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"626","DOI":"10.18632\/oncotarget.27922","article-title":"Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine","volume":"12","author":"Singh","year":"2021","journal-title":"Oncotarget"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"30","DOI":"10.21037\/tcr.2017.01.09","article-title":"Advances on immunotherapy in breast cancer","volume":"6","author":"Athreya","year":"2017","journal-title":"Transl Cancer Res"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"e0168669","DOI":"10.1371\/journal.pone.0168669","article-title":"Claudin-low breast cancer; clinical & pathological characteristics","volume":"12","author":"Dias","year":"2017","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"101977","DOI":"10.1016\/j.artmed.2020.101977","article-title":"Prediction of breast cancer distant recurrence using natural language processing and knowledge-guided convolutional neural network","volume":"110","author":"Wang","year":"2020","journal-title":"Artif Intell Med"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.tcb.2008.01.007","article-title":"How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?","volume":"18","author":"Chipuk","year":"2008","journal-title":"Trends Cell Biol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1038\/onc.2016.95","article-title":"HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24","volume":"35","author":"Teo","year":"2016","journal-title":"Oncogene"},{"key":"ref55","first-page":"265","article-title":"Diagnosis, prognosis, and treatment of triple-negative breast cancer: a review","volume":"17","author":"Jie","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12916-015-0425-1","article-title":"PARP inhibitors in the management of breast cancer: current data and future prospects","volume":"13","author":"Livraghi","year":"2015","journal-title":"BMC Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: american society of clinical oncology guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Wei","year":"2002","journal-title":"Cell Res"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1007\/s00210-024-03042-6","article-title":"The Lawson-loaded \u03b2-cyclodextrin nanocarriers (LB-NCs) a novel targeted cancer cell in stomach and breast cancer as a drug delivery system","volume":"397","author":"Alboabdullah","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/sci.2018.02.02","article-title":"Targeting notch signaling pathway of cancer stem cells","volume":"5","author":"Venkatesh","year":"2018","journal-title":"Stem Cell Investig"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"13899","DOI":"10.18632\/oncotarget.4224","article-title":"Targeting the hedgehog signaling pathway in cancer: beyond smoothened","volume":"6","author":"Gonnissen","year":"2015","journal-title":"Oncotarget"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"44673","DOI":"10.1038\/srep44673","article-title":"Neoadjuvant chemotherapy creates surgery opportunities for inoperable locally advanced breast cancer","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1208\/s12249-022-02212-0","article-title":"The optimized formulation of tamoxifen-loaded niosomes efficiently induced apoptosis and cell cycle arrest in breast cancer cells","volume":"23","author":"Akbarzadeh","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/pharmaceutics16010079","article-title":"Curcumin for treating breast cancer: a review of molecular mechanisms, combinations with anticancer drugs, and nanosystems","volume":"16","author":"Zhu","year":"2024","journal-title":"Pharmaceutics"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"155600","DOI":"10.1016\/j.phymed.2024.155600","article-title":"Natural products and derivatives for breast cancer treatment: from drug discovery to molecular mechanism","volume":"129","author":"Zhang","year":"2024","journal-title":"Phytomedicine"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"104707","DOI":"10.1016\/j.chemphyslip.2018.11.009","article-title":"Cabazitaxel and thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer","volume":"224","author":"Kommineni","year":"2019","journal-title":"Chem Phys Lipids"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"152001","DOI":"10.1016\/j.bbrc.2025.152001","volume":"771","author":"Sharma","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3892\/ijo.2014.2769","article-title":"Wedelolactone inhibits breast cancer-induced os-teoclastogenesis by decreasing Akt\/mTOR signaling","volume":"46","author":"Hsieh","year":"2015","journal-title":"Int J Oncol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1021\/acs.bioconjchem.9b00028","article-title":"Systemic delivery of tumor-targeting siRNA Nanoparticles against an oncogenic LncRNA facilitates effective triple-negative breast cancer therapy","volume":"30","author":"Vaidya","year":"2019","journal-title":"Bioconjug Chem"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2147\/IJN.S226186","article-title":"Subcellular performance of nanoparticles in cancer therapy","volume":"15","author":"Liu","year":"2020","journal-title":"Int J Nanomed"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.semcancer.2015.11.001","article-title":"Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms","volume":"40\u201341","author":"Sinha","year":"2016","journal-title":"Semin Cancer Biol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.3390\/ijms22094774","article-title":"Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors","volume":"22","author":"Indini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1108242","DOI":"10.3389\/fonc.2023.1108242","article-title":"The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+\/PIK3CA mutant breast cancer","volume":"13","author":"Cataldo","year":"2023","journal-title":"Front Oncol"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"155746","DOI":"10.1016\/j.phymed.2024.155746","article-title":"Paris saponin VII inhibits triple-negative breast cancer by targeting the MEK\/ERK\/STMN1 signaling axis","volume":"130","author":"Zhang","year":"2024","journal-title":"Phytomedicine"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3892\/ijo.2015.3003","article-title":"The PARP inhibitor AZD2281 (Olaparib) induces autophagy\/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells","volume":"47","author":"Arun","year":"2015","journal-title":"Int J Oncol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/adfm.200801271","article-title":"Doxorubicin-conjugated immuno-nanoparticles for intracellular anti-cancer drug delivery","volume":"19","author":"Shi","year":"2009","journal-title":"Adv Funct Mater"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40005-019-00459-7","article-title":"Recent advances of nanotechnology for the delivery of anticancer drugs for breast cancer treatment","volume":"50","author":"Tran","year":"2020","journal-title":"J Pharm Investig"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41551-020-0581-2","article-title":"Enhancement of the blood-circulation time and performance of nanomedicines via the forced clearance of erythrocytes","volume":"4","author":"Nikitin","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"100800","DOI":"10.1016\/j.nantod.2019.100800","article-title":"Engineered nanomedicines with enhanced tumor penetration","volume":"29","author":"Ding","year":"2019","journal-title":"Nano Today"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-98638-w","article-title":"Effects of hypoxia and nanocarrier size on pH-responsive nano-delivery system to solid tumors","volume":"11","author":"Soltani","year":"2021","journal-title":"Sci Rep"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jare.2018.06.005","article-title":"Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review","volume":"15","author":"Hossen","year":"2019","journal-title":"J Adv Res"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.2147\/DDDT.S219489","article-title":"Smart targeting to improve cancer therapeutics","volume":"13","author":"Morales-Cruz","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2024.10.010","article-title":"Biomaterials to regulate tumor extracellular matrix in immunotherapy","volume":"376","author":"Zhang","year":"2024","journal-title":"J Control Release"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.3390\/molecules26195905","article-title":"Controlled drug delivery systems: current status and future directions","volume":"26","author":"Adepu","year":"2021","journal-title":"Molecules"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-025-01684-4","article-title":"Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance","volume":"18","author":"Shang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.2217\/nnm-2017-0202","article-title":"The use of nanoparticulates to treat breast cancer","volume":"12","author":"Tang","year":"2017","journal-title":"Nanomed"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1002\/jcb.29651","article-title":"Development of a novel liposomal nanoparticle formulation of cisplatin to breast cancer therapy","volume":"121","author":"Ghafari","year":"2020","journal-title":"J Cell Biochem"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"44183","DOI":"10.1021\/acsomega.3c06605","volume":"8","author":"Gilani","year":"2023","journal-title":"ACS Omega"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"112220","DOI":"10.1016\/j.mtcomm.2025.112220","article-title":"Formulation of curcumin loaded solid lipid nano particles following response surface methodology to improve the anti-cancer activity in triple-negative breast cancer cells","volume":"45","author":"Sarkar","year":"2025","journal-title":"Mater Today Commun"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"107077","DOI":"10.1016\/j.jddst.2025.107077","volume":"110","author":"Peleje","year":"2025","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s43094-023-00494-0","article-title":"Design, development, and evaluation of docetaxeloaded niosomes for the treatment of breast cancer","volume":"9","author":"Gaikwad","year":"2023","journal-title":"Future J Pharm Sci"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijbiomac.2019.02.129","article-title":"Aptamer functionalized curcumin-loaded human serum albumin (HSA) nano-particles for targeted delivery to HER-2 positive breast cancer cells","volume":"130","author":"Saleh","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.3390\/molecules27144634","volume":"27","author":"Honarvari","year":"2022","journal-title":"Molecules"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"855294","DOI":"10.3389\/fphar.2022.855294","article-title":"Design and characterization of paclitaxel-loaded polymeric nanoparticles decorated with trastuzumab for the effective treatment of breast cancer","volume":"13","author":"Sakhi","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref97","first-page":"515","article-title":"Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer","volume":"12","author":"Cabeza","year":"2022","journal-title":"Bioimpacts"},{"key":"ref98","first-page":"112","volume":"26","author":"Khazaei","year":"2024","journal-title":"Cell Journal"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"105943","DOI":"10.1016\/j.ejps.2021.105943","article-title":"Folic acid-doxorubicin polymeric nanocapsules: a promising formulation for the treatment of triple-negative breast cancer","volume":"165","author":"C\u00e9","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"12796","DOI":"10.1039\/D4RA00610K","article-title":"Construction of glutathione-responsive paclitaxel prodrug nanoparticles for image-guided targeted delivery and breast cancer therapy","volume":"14","author":"Ma","year":"2024","journal-title":"RSC Adv"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s12951-024-02694-z","article-title":"Determining M2 macrophages content for the anti-tumor effects of metal-organic framework-encapsulated pazopanib nanoparticles in breast cancer","volume":"22","author":"Xu","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"8471331","DOI":"10.1155\/2022\/8471331","article-title":"Mesoporous silica nanoparticles loaded with resveratrol are used for targeted breast cancer therapy","volume":"2022","author":"Gu","year":"2022","journal-title":"J Oncol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cjce.25267","article-title":"Synergistic effects of graphene quantum dots nanocarriers and folic acid targeting agent on enhanced killing of breast cancer cells by tamoxifen","volume":"102","author":"Ghanbari","year":"2024","journal-title":"Canadian J Chem Eng"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1038\/s41598-025-90107-y","article-title":"Advancing triple-negative breast cancer treatment through peptide decorated solid lipid nanoparticles for paclitaxel delivery","volume":"15","author":"Rahdari","year":"2025","journal-title":"Sci Rep"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"114504","DOI":"10.1016\/j.colsurfb.2025.114504","volume":"249","author":"G\u00f3mez-Pastor","year":"2025","journal-title":"Col-loids Surf B Biointerfaces"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/17435889.2025.2501526","article-title":"Anticancer efficacy of dual-loaded SLNs with doxorubicin (DOX) and pterostilbene (PTS): formulation, characterization, and evaluation for breast cancer","volume":"20","author":"Marwah","year":"2025","journal-title":"Nanomedicine"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.drudis.2016.09.013","article-title":"Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery","volume":"22","author":"Sharma","year":"2017","journal-title":"Drug Discov Today"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/CAD.0000000000000098","article-title":"Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for breast cancer therapy","volume":"25","author":"Madan","year":"2014","journal-title":"Anti-cancer Drugs"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.addr.2008.02.012","article-title":"Therapeutic and diagnostic applications of dendrimers for cancer treatment","volume":"60","author":"Wolinsky","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/molecules23040938","article-title":"Dendrimers for drug delivery","volume":"23","author":"Chauhan","year":"2018","journal-title":"Molecules"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.3390\/molecules25173982","article-title":"Applications and limitations of dendrimers in biomedicine","volume":"25","author":"Aurelia Chis","year":"2020","journal-title":"Molecules"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3390\/molecules22091401","article-title":"Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy","volume":"22","author":"Mendes","year":"2017","journal-title":"Molecules"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/biom9080330","article-title":"Cytotoxicity of dendrimers","volume":"9","author":"Janaszewska","year":"2019","journal-title":"Biomolecules"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"7891","DOI":"10.2147\/IJN.S328135","article-title":"Drug delivery of natural products through nanocarriers for effective breast cancer therapy: a comprehensive review of literature","volume":"16","author":"Yap","year":"2021","journal-title":"Int J Nanomed"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1039\/D2TB01855A","article-title":"Novel manganese and polyester dendrimer-based theranostic na-noparticles for MRI and breast cancer therapy","volume":"11","author":"Zhou","year":"2022","journal-title":"J Mater Chem B"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.actbio.2023.04.003","article-title":"A tumor microenvironment-responsive core-shell tecto den-drimer nanoplatform for magnetic resonance imaging-guided and cuproptosis-promoted chemo-chemodynamic therapy","volume":"164","author":"Ni","year":"2023","journal-title":"Acta Biomater"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"213047","DOI":"10.1016\/j.bioadv.2022.213047","article-title":"Lapatinib- and fulves-trant-PAMAM dendrimer conjugates promote apoptosis in chemotherapy-induced senescent breast cancer cells with different receptor status","volume":"140","author":"Lewi\u0144ska","year":"2022","journal-title":"Biomater Adv"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"33439","DOI":"10.1021\/acsami.5c03560","article-title":"Highly adaptable dendrimer gel nanoparticles with dual targeting of uPAR and ribonucleotide reductase R2 for better retention and improved therapeutic outcomes in triple-negative breast cancer","volume":"17","author":"Chuang","year":"2025","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"138526","DOI":"10.1016\/j.molstruc.2024.138526","article-title":"Synthesis, characterization and biological activities of nitrophe-nol substituted phosphazene dendrimers","volume":"1312","author":"Gholamrezazadeh","year":"2024","journal-title":"J Mol Struct"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.actbio.2024.05.035","volume":"183","author":"Huang","year":"2024","journal-title":"Acta Biomater"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2174\/138945011795906570","article-title":"Lipid-based drug delivery systems for cancer treat-ment","volume":"12","author":"Arias","year":"2011","journal-title":"Curr Drug Targets"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3390\/nano9040638","article-title":"Lipid-based nanoparticles: application and recent advances in cancer treatment","volume":"9","author":"Garc\u00eda-Pinel","year":"2019","journal-title":"Nanomater"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Release"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1124\/pr.115.012070","article-title":"Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come","volume":"68","author":"Yingchoncharoen","year":"2016","journal-title":"Pharmacol Rev"},{"key":"ref125","first-page":"514","article-title":"Cancer immunotherapy, Part 3: challenges and future trends","volume":"42","author":"Ventola","year":"2017","journal-title":"P T"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"770","DOI":"10.12688\/f1000research.25142.2","volume":"9","author":"Singh","year":"2021","journal-title":"F1000Res"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/08982104.2023.2248505","volume":"34","author":"Raikwar","year":"2024","journal-title":"J Liposome Res"},{"key":"ref128","first-page":"100173","article-title":"Stilbenes in breast cancer treatment: nanostilbenes an ap-proach to improve therapeutic efficacy","volume":"6","author":"Ahamad","year":"2025","journal-title":"Pharmacol Res-Nat Prod"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2147\/IJN.S382109","article-title":"Combinatorial polydopamine-liposome nanoformulation as an effective anti-breast cancer therapy","volume":"18","author":"Lu","year":"2023","journal-title":"Int J Nanomed"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"16737","DOI":"10.1038\/s41598-025-00211-2","article-title":"Liposomal oncolytic adenovirus as a neoadjuvant therapy for triple-negative breast cancer","volume":"15","author":"Shah","year":"2025","journal-title":"Sci Rep"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s13346-023-01339-2","article-title":"Development of doxorubicin-encapsulated magnetic liposome@PEG for treatment of breast cancer in BALB\/c mice","volume":"13","author":"Maghsoudi","year":"2023","journal-title":"Drug Deliv Transl Res"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jconrel.2021.12.001","article-title":"Liposome-encapsulated anthraquinone improves efficacy and safety in triple negative breast cancer","volume":"342","author":"George","year":"2022","journal-title":"J Control Release"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/08982104.2021.2001499","article-title":"Co-delivery of F7 and crizotinib by thermosensitive liposome for breast cancer treatment","volume":"32","author":"Li","year":"2022","journal-title":"J Liposome Res"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s11095-014-1560-7","volume":"32","author":"Shemesh","year":"2015","journal-title":"Pharm Res"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/08982104.2024.2321528","volume":"34","author":"Vozgirdaite","year":"2024","journal-title":"J Liposome Res"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"124583","DOI":"10.1016\/j.ijpharm.2024.124583","article-title":"Versatile thermo-sensitive liposomes with HSP inhibition and anti-inflammation for synergistic chemo-photothermal to inhibit breast cancer metastasis","volume":"664","author":"Li","year":"2024","journal-title":"Int J Pharm"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1120009X.2025.2484078","article-title":"Liposome-assisted combination chemotherapy improves the anti-proliferation and anti-angiogenesis response of cisplatin in breast cancer; experimental and computational study","volume":"9","author":"Valinezhadi","year":"2025","journal-title":"J Chemother"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"e0194179","DOI":"10.1371\/journal.pone.0194179","article-title":"Niosomes, an alternative for liposomal delivery","volume":"13","author":"Bartelds","year":"2018","journal-title":"PLoS One"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejpb.2019.08.015","article-title":"Recent advances in non-ionic surfactant vesicles (niosomes): fab-rication, characterization, pharmaceutical and cosmetic applications","volume":"144","author":"Chen","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1208\/s12249-025-03037-3","article-title":"Optimization of capecitabine-loaded niosomes using factorial design: an approach for enhanced drug release and cytotoxicity in breast cancer","volume":"26","author":"Sabale","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"ref141","first-page":"100237","article-title":"Evaluating a targeted Palbo-ciclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells","volume":"7","author":"Saharkhiz","year":"2024","journal-title":"Int J Pharm X"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"123686","DOI":"10.1016\/j.ijbiomac.2023.123686","article-title":"Preparation and physicochemical properties of cisplatin and doxorubicin encapsulated by niosome alginate nanocarrier for cancer therapy","volume":"235","author":"Safari Sharafshadeh","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11033-025-10241-8","volume":"52","author":"Fakeri","year":"2025","journal-title":"Mol Biol Rep"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"8809","DOI":"10.53730\/ijhs.v6nS5.11794","article-title":"Niosomes: a promising nonionic surfactant vesicular system for enhancement of anticancer effect of phytochemicals","volume":"6","author":"Jawale","year":"2022","journal-title":"Ijhs"},{"key":"ref145","doi-asserted-by":"crossref","first-page":"100837","DOI":"10.1016\/j.mtbio.2023.100837","article-title":"Current advances in niosomes applications for drug delivery and cancer treatment","volume":"23","author":"Moammeri","year":"2023","journal-title":"Mater Today Bio"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"10712","DOI":"10.3390\/ijms251910712","article-title":"Solid lipid nanoparticles, an alternative for the treatment of triple-negative breast cancer","volume":"25","author":"Llaguno-Munive","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/adt.2024.125","article-title":"Enhanced anticancer efficiency of curcumin co-loaded lawsone solid lipid nanoparticles against MCF-7 breast cancer cell lines: optimization by statistical JMP software-based experimental approach","volume":"23","author":"Penugonda","year":"2025","journal-title":"Assay Drug Dev Technol"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/20415990.2025.2457314","article-title":"A quality-by-design approach to develop abemaciclib solid lipid nanoparticles for targeting breast cancer cell lines","volume":"16","author":"Chin","year":"2025","journal-title":"Ther Deliv"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1080\/17435889.2024.2364585","article-title":"Optimization of atorvastatin and quercetin-loaded solid lipid nanoparticles using Box-Behnken design","volume":"19","author":"Lalchandani","year":"2024","journal-title":"Nanomedicine"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"106638","DOI":"10.1016\/j.ejps.2023.106638","article-title":"Nanostructured lipid carriers loaded into in situ gels for breast cancer local treatment","volume":"192","author":"Passos","year":"2024","journal-title":"Eur J Pharm Sci"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2174\/0115672018309370240708113038","volume":"22","author":"Hadi Sultan","year":"2024","journal-title":"Curr Drug Deliv"},{"key":"ref152","doi-asserted-by":"crossref","first-page":"124954","DOI":"10.1016\/j.ijpharm.2024.124954","article-title":"Rapamycin-loaded nanostructured lipid carrier modified with folic acid intended for breast cancer therapy","volume":"668","author":"Rodero","year":"2025","journal-title":"Int J Pharm"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/acs.molpharmaceut.4c01122","article-title":"Development and preclinical assessment of a palbociclib nanostructured lipid carrier for potential breast cancer management","volume":"22","author":"Nehal","year":"2025","journal-title":"Mol Pharm"},{"key":"ref154","doi-asserted-by":"crossref","first-page":"105414","DOI":"10.1016\/j.jddst.2024.105414","article-title":"Chitosan coated lipid carriers as nanoplatform for repurposed anti-breast cancer activity of niclosamide","volume":"93","author":"Elkholy","year":"2024","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"e13292","DOI":"10.1111\/dth.13292","article-title":"Emerging trends in nanomedicine for topical delivery in skin disorders: current and translational approaches","volume":"33","author":"Pandey","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10837450.2016.1212882","article-title":"A review of semi-synthetic biopolymer complexes: modified polysaccharide nano-carriers for enhancement of oral drug bioavailability","volume":"22","author":"Sithole","year":"2017","journal-title":"Pharm Dev Technol"},{"key":"ref157","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/21691401.2018.1457039","article-title":"Nanoparticles as carriers for drug delivery in cancer","volume":"46","author":"Dadwal","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref158","doi-asserted-by":"crossref","first-page":"213270","DOI":"10.1016\/j.bioadv.2022.213270","article-title":"Effective breast cancer therapy based on palmitic acid-loaded PLGA nanoparticles","volume":"145","author":"He","year":"2023","journal-title":"Biomater Adv"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"139820","DOI":"10.1016\/j.molstruc.2024.139820","article-title":"Construction of a nano-fluorescent polymer drug delivery system for breast cancer treatment","volume":"1321","author":"Wang","year":"2025","journal-title":"J Mol Struct"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"106663","DOI":"10.1016\/j.jddst.2025.106663","article-title":"Cytotoxic potential of polymeric nanoparticles loaded with Brazilian red propolis in breast cancer","volume":"105","author":"Justino","year":"2025","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s13346-022-01273-9","article-title":"Exploring paclitaxel-loaded adenosine-conjugated PEGylated PLGA nanoparticles for targeting triple-negative breast cancer","volume":"13","author":"Chaudhari","year":"2023","journal-title":"Drug Deliv Transl Res"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1021\/acsomega.2c06359","article-title":"Fabrication, optimization, and evaluation of paclitaxel and curcumin coloaded PLGA nanoparticles for improved antitumor activity","volume":"8","author":"Hu","year":"2023","journal-title":"ACS Omega"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/10837450.2022.2120003","article-title":"Co-delivery of curcumin and Bcl-2 siRNA to enhance therapeutic effect against breast cancer cells using PEI-functionalized PLGA nanoparticles","volume":"27","author":"Mohammad Gholinia Sarpoli","year":"2022","journal-title":"Pharm Dev Technol"},{"key":"ref164","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/02652048.2021.2014586","article-title":"Hyaluronic acid-coated and Olaparib-loaded PEI\u2013PLGA nano-particles for the targeted therapy of triple negative breast cancer","volume":"39","author":"Hu","year":"2022","journal-title":"J Microencapsul"},{"key":"ref165","doi-asserted-by":"crossref","first-page":"108127","DOI":"10.1016\/j.bioorg.2025.108127","article-title":"pH-sensitive phthalocyanine-loaded polymeric nanoparticles as a novel treatment strategy for breast cancer","volume":"155","author":"Malarz","year":"2025","journal-title":"Bioorg Chem"},{"key":"ref166","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10924-022-02654-4","article-title":"Biodegradable PEG-PCL nanoparticles for codelivery of MUC1 inhibitor and doxorubicin for the confinement of triple-negative breast cancer","volume":"31","author":"Behl","year":"2023","journal-title":"J Polym Environ"},{"key":"ref167","doi-asserted-by":"crossref","first-page":"132146","DOI":"10.1016\/j.ijbiomac.2024.132146","article-title":"Doxorubicin encapsulated blend of sitagliptin-lignin polymeric drug delivery system for effective combination therapy against cancer","volume":"269","author":"Liaqat","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"ref168","doi-asserted-by":"crossref","first-page":"e202400207","DOI":"10.1002\/star.202400207","article-title":"Thiolated and carboxymethylated jackfruit seed starch nanocrystals as polymeric drug carriers for curcumin delivery to cancer cells","volume":"7","author":"Balogun-Agbaje","year":"2025","journal-title":"Starch-St\u00e4rke"},{"key":"ref169","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s13346-023-01443-3","article-title":"Folic acid grafted mixed polymeric micelles as a tar-geted delivery strategy for tamoxifen citrate in treatment of breast cancer","volume":"14","author":"Nasr","year":"2024","journal-title":"Drug Deliv Transl Res"},{"key":"ref170","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/10837450.2025.2460732","article-title":"Development of PLGA-SPC3 functionalized gefitinib mesoporous silica nano-scaffolds for breast cancer targeting: biodistribution and cytotoxicity analysis","volume":"30","author":"Sah","year":"2025","journal-title":"Pharm Dev Technol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"121434","DOI":"10.1016\/j.carbpol.2023.121434","article-title":"Folate-modified carboxymethyl chitosan-based drug delivery system for breast cancer specific combination therapy via regulating mitochondrial calcium concentration","volume":"323","author":"Lv","year":"2024","journal-title":"Carbohydr Polym"},{"key":"ref172","doi-asserted-by":"crossref","first-page":"106431","DOI":"10.1016\/j.jddst.2024.106431","article-title":"Synergistic effects of doxorubicin PLGA nanoparticles and simvastatin loaded in silk films for local treatment of breast cancer","volume":"104","author":"Rakhshani","year":"2025","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref173","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3390\/nano9091329","article-title":"Developing protein-based nanoparticles as versatile delivery systems for cancer therapy and imaging","volume":"9","author":"Sandra","year":"2019","journal-title":"Nanomater"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/1878-0261.13216","article-title":"Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach","volume":"16","author":"D\u00edaz","year":"2022","journal-title":"Mol Oncol"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s13193-021-01374-w","article-title":"Prevalence of molecular subtypes in operated cases of breast cancer and its clinicopathological correlation: a single institute study from a tertiary cancer centre in North India","volume":"12","author":"Jain","year":"2021","journal-title":"Indian J Surg Oncol"},{"key":"ref176","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/cac2.12358","article-title":"Breast cancer: an up-to-date review and future perspectives","volume":"42","author":"Hong","year":"2022","journal-title":"Cancer Commun"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"138152","DOI":"10.1016\/j.ijbiomac.2024.138152","article-title":"The interaction of cinchonine and immunoglobulin G and the development of a nanocomplex with improved anti-breast cancer activity","volume":"287","author":"Wang","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"ref178","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1021\/acs.biomac.3c01104","article-title":"Silk protein-based nanoporous microsphere for controllable drug delivery through self-assembly in ionic liquid system","volume":"25","author":"Deng","year":"2024","journal-title":"Biomacromolecules"},{"key":"ref179","doi-asserted-by":"crossref","first-page":"138152","DOI":"10.1016\/j.colsurfb.2024.114399","article-title":"Combination therapy of Lapatinib\/Letrozole-based protein-vitamin nanoparticles to enhance the therapeutic effectiveness in drug-resistant breast cancer","volume":"247","author":"Are","year":"2025","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/20415990.2024.2433938","article-title":"Bioinspired caffeic acid-laden milk protein-based nanoparticles targeting folate receptors for breast cancer treatment","volume":"16","author":"Safwat","year":"2024","journal-title":"Ther Deliv"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1021\/nn401196a","article-title":"Carbon-based nanomaterials: multifunctional materials for biomedical engineering","volume":"7","author":"Cha","year":"2013","journal-title":"ACS Nano"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fphar.2018.01401","article-title":"Carbon-based nanomaterials for biomedical applications: a recent study","volume":"9","author":"Maiti","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref183","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s00604-023-05761-8","article-title":"Synthesis of single-walled carbon nanotubes functionalized with platinum nanoparticles to sense breast cancer cells in 4T1 model to X-ray radiation","volume":"190","author":"Aghaei","year":"2023","journal-title":"Mikrochim Acta"},{"key":"ref184","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s00204-024-03779-2","article-title":"Carbon nanotubes conjugated with cisplatin activate different apoptosis signaling pathways in 2D and 3D-spheroid triple-negative breast cancer cell cultures: a comparative study","volume":"98","author":"Badea","year":"2024","journal-title":"Arch Toxicol"},{"key":"ref185","doi-asserted-by":"crossref","first-page":"114562","DOI":"10.1016\/j.colsurfb.2025.114562","article-title":"Carbon nanoparticles-Fe(II) complex combined with soraf-enib for ferroptosis-induced antitumor effects in triple-negative breast cancer","volume":"250","author":"Xie","year":"2025","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref186","doi-asserted-by":"crossref","first-page":"129841","DOI":"10.1016\/j.bbagen.2020.129841","article-title":"Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer","volume":"1865","author":"Basu","year":"2021","journal-title":"Biochim Et Biophys Acta BBA-Gen Subj"},{"key":"ref187","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/pharmaceutics13111982","article-title":"Manganese-doped n-hydroxyphthalimide-derived carbon dots\u2014theranostics applications in experimental breast cancer models","volume":"13","author":"Tiron","year":"2021","journal-title":"Pharmaceutics"},{"key":"ref188","doi-asserted-by":"crossref","first-page":"112586","DOI":"10.1016\/j.msec.2021.112586","volume":"134","author":"Radzi","year":"2022","journal-title":"Biomat Adv"},{"key":"ref189","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jconrel.2023.11.005","article-title":"Dacarbazine-primed carbon quantum dots coated with breast cancer cell-derived exosomes for improved breast cancer therapy","volume":"365","author":"Tiwari","year":"2024","journal-title":"J Controll Release"},{"key":"ref190","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1039\/D4NA00834K","article-title":"Targeted NIR-triggered doxorubicin release using carbon dots-poly(ethylene glycol)\u2013folate conjugates for breast cancer treatment","volume":"7","author":"Varvar\u00e0","year":"2025","journal-title":"Nanoscale Adv"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.2147\/IJN.S471360","article-title":"The advancing role of nanocomposites in cancer diagnosis and treatment","volume":"19","author":"Andoh","year":"2024","journal-title":"Int J Nanomed"},{"key":"ref192","doi-asserted-by":"crossref","first-page":"116462","DOI":"10.1016\/j.envres.2023.116462","article-title":"A new formulation of Ni\/Zn bimetallic nanocomposite and evaluation of its applications for pollution removal, photocatalytic, electrochemical sensing, and anti-breast cancer","volume":"233","author":"Li","year":"2023","journal-title":"Environ Res"},{"key":"ref193","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.semcancer.2019.12.016","article-title":"Nanomedicine in treatment of breast cancer-A challenge to conventional therapy","volume":"69","author":"Afzal","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"103922","DOI":"10.1016\/j.jddst.2022.103922","article-title":"A tumor-targeted delivery of oral isoliquiritigenin through encapsulated zein phosphatidylcholine hybrid nanoparticles prevents triple-negative breast cancer","volume":"79","author":"Wang","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref195","doi-asserted-by":"crossref","first-page":"230549","DOI":"10.4491\/eer.2023.549","article-title":"Review on metallic nanoparticles induced toxicity on renal function and overall health of kidneys","volume":"29","author":"Waris","year":"2024","journal-title":"Environ Eng Res"},{"key":"ref196","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-3-319-47754-1_4","volume":"947","author":"Graham","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"ref197","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/17435889.2024.2443385","article-title":"Nanotoxicology: developments and new insights","volume":"20","author":"Abonyi","year":"2025","journal-title":"Nanomed"},{"key":"ref198","doi-asserted-by":"crossref","first-page":"102881","DOI":"10.1016\/j.cis.2023.102881","article-title":"What function of nanoparticles is the primary factor for their hyper-toxicity?","volume":"314","author":"Ali","year":"2023","journal-title":"Adv Colloid Interface Sci"},{"key":"ref199","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2217\/nnm.11.19","article-title":"Nanoparticle PEGylation for imaging and therapy","volume":"6","author":"Jokerst","year":"2011","journal-title":"Nanomed"},{"key":"ref200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s11671-018-2728-6","article-title":"Insight into cellular uptake and intracellular trafficking of nanoparticles","volume":"13","author":"Foroozandeh","year":"2018","journal-title":"Nanoscale Res Lett"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-3-030-72173-2_5","author":"John","year":"2022","journal-title":"New frontiers in environmental toxicology"},{"key":"ref202","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.2174\/1381612825666190117094250","article-title":"Recent interventions for nanotechnology based drug products: insights into the regulatory aspects","volume":"24","author":"Sarwal","year":"2019","journal-title":"Curr Pharm Des"},{"key":"ref203","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/B978-0-12-813629-4.00016-4","author":"Rahman","year":"2018","journal-title":"Nanoscale fabrication, optimization, scale-up and biological aspects of pharmaceutical nanotechnology"},{"key":"ref204","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fchem.2018.00360","article-title":"Nanomedicine: principles, properties, and regulatory issues","volume":"6","author":"Soares","year":"2018","journal-title":"Front Chem"},{"key":"ref205","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.nano.2015.12.376","article-title":"Challenges of clinical translation in nanomedicine: a qualitative study","volume":"12","author":"Satalkar","year":"2016","journal-title":"Nanomed"},{"key":"ref206","unstructured":"NIH. ClinicalTrials.gov [Internet]. [cited 2025 Mar 12]. Available from: https:\/\/clinicaltrials.gov\/."},{"key":"ref207","unstructured":"Telli ML. A phase 1\/2 Trial of ARV-471 alone and in combination with Palbociclib (IBRANCE\u00ae) in patients with ER+\/HER2- locally advanced or metastatic breast cancer [Internet]. Trial ID: NCT04072952. [cited 2025 Mar 12]. Available from: https:\/\/stanfordhealthcare.org\/trials\/a\/NCT04072952.html."},{"key":"ref208","unstructured":"Riaz F. A Phase-3, open-label, randomized study of Dato-DXd versus investigator\u2019s choice of chemotherapy (ICC) in participants with inoperable or metastatic HR-Positive, HER2-negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy (TROPION-Breast01) [Internet]. Trial ID: NCT05104866. [cited 2025 Mar 13]. Available from: https:\/\/clinicaltrials.stanford.edu\/trials\/a\/NCT05104866.html."},{"key":"ref209","unstructured":"NIH. A safety study of SGN-LIV1A in breast cancer patients [Internet]. Trial ID: NCT01969643. [cited 2025 Mar 13]. Available from: https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2013-02245."},{"key":"ref210","unstructured":"Klimberg VS. Axillary reverse mapping in preventing lymphedema in patients with breast cancer undergoing axillary lymph node dissection. division of cancer prevention [Internet]. NCT ID: NCT03927027. [cited 2025 Mar 13]. Available from: https:\/\/prevention.cancer.gov\/clinical-trials\/clinical-trials-search\/nct03927027."},{"key":"ref211","unstructured":"Georgia\u2019s Online Cancer Information Center. I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer. NCT ID: NCT01042379. [cited 2025 Mar 13]. Available from: https:\/\/www.georgiacancerinfo.org\/clinical-trials\/detail\/2422."},{"key":"ref212","unstructured":"A study of tucatinib plus trastuzumab deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04) [Internet]. NCT ID: NCT04539938. [cited 2025 Mar 13]. Available from: https:\/\/ctv.veeva.com\/study\/a-study-of-tucatinib-plus-trastuzumab-deruxtecan-in-her2-breast-cancer."},{"key":"ref213","unstructured":"Atezolizumab + Sacituzumab govitecan to prevent recurrence in TNBC (ASPRIA). [Internet]. NCT ID: NCT04434040. [cited 2025 Mar 13]. Available from: https:\/\/www.smartpatients.com\/trials\/NCT04434040."},{"key":"ref214","unstructured":"Avelumab with Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients with Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer - NCI [Internet]. NCT ID: NCT03971409. [cited 2025 Mar 13]. Available from: https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2019-01531."},{"key":"ref215","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41416-019-0391-z","article-title":"A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients","volume":"120","author":"Fujiwara","year":"2019","journal-title":"Br J Cancer"},{"key":"ref216","first-page":"77","article-title":"Nanosomal docetaxel lipid suspension-based chemotherapy in breast cancer: results from a multicenter retrospective study","volume":"12","author":"Subramanian","year":"2020","journal-title":"Breast Cancer"},{"key":"ref217","unstructured":"Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy. Treatment of triple-negative breast cancer with albumin-bound paclitaxel as neoadjuvant therapy: a prospective RCT [Internet]. NCT ID: NCT04137653. [cited 2025 Mar 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04137653."},{"key":"ref218","unstructured":"Single-arm, multi-center clinical study of pyrotinib maleate tablets combined with albu-min-bound paclitaxel and trastuzumab in neoadjuvant treatment of Her2-positive early or locally advanced breast cancer [Internet]. NCT ID: NCT04917900. [cited 2025 Mar 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04917900."},{"key":"ref219","unstructured":"Efficacy and safety of paclitaxel polymeric micelles for injection in the treatment of metastatic breast cancer [Internet]. NCT ID: NCT06143553. [cited 2025 Mar 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06143553."},{"key":"ref220","unstructured":"Clinical efficacy and safety of paclitaxel polymeric micelles for injection in the treatment of pa-tients with taxans-resistant pancreatic adenocarcinoma, cholangiocarcinoma, lung cancer, gastric cancer, esophageal carcinoma, or breast cancer [Internet]. NCT ID: NCT06199895. [cited 2025 Mar 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06199895."},{"key":"ref221","unstructured":"OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer [Internet]. NCT ID: NCT05949021. [cited 2025 Mar 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05949021."},{"key":"ref222","unstructured":"The efficacy and safety of eutideron, etoposide, and bevacizumab in patients with brain metas-tases from breast cancer. [Internet]. NCT ID: NCT05781633. [cited 2025 Mar 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05781633?cond=Breast%20Cancer&rank=5."},{"key":"ref223","unstructured":"UCSF BRCA 1 Gene Mutation Trial\u2192Denosumab on preventing breast cancer in women with a brca1 germline mutation [Internet]. NCT ID: NCT04711109. [cited 2025 Mar 13]. Available from: https:\/\/clinicaltrials.ucsf.edu\/trial\/NCT04711109."},{"key":"ref224","unstructured":"FDA. Drugs trials snapshot: iTOVEBI [Internet]. [cited 2025 Jun 1]. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drugs-trials-snapshot-itovebi."},{"key":"ref225","unstructured":"FDA. FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutatFDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer [Internet]. [cited 2025 Jun 1]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer."},{"key":"ref226","unstructured":"FDA. FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer [Internet]. [cited 2025 Jun 1]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2."},{"key":"ref227","unstructured":"FDA. FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer [Internet]. [cited 2025 Jun 1]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast."},{"key":"ref228","unstructured":"FDA. FDA approves capivasertib with fulvestrant for breast cancer [Internet]. [cited 2025 Jun 1]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-capivasertib-fulvestrant-breast-cancer."},{"key":"ref229","unstructured":"Endocrine therapy with or without abemaciclib (LY2835219) following surgery in participants with breast cancer [Internet]. [cited 2025 Jun 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03155997."},{"key":"ref230","unstructured":"Study assessing the efficacy and safety of alpelisib plus fulvestrant in men and postmenopausal women with advanced breast cancer wich progressed on or after aromatase inhibitor treatment [Internet]. [cited 2025 Jun 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02437318#study-overview."},{"key":"ref231","unstructured":"FDA. FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer [Internet]. [cited 2025 Jun 1]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sacituzumab-govitecan-hziy-hr-positive-breast-cancer."},{"key":"ref232","unstructured":"FDA. FDA approves Kisqali with an aromatase inhibitor and Kisqali Femara Co-Pack for early high-risk breast cancer [Internet]. [cited 2025 Jun 1]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-kisqali-aromatase-inhibitor-and-kisqali-femara-co-pack-early-high-risk-breast-cancer."},{"key":"ref233","author":"Johnson","year":"2024","journal-title":"inventors; Chem-Master International Inc., Research foundation of the State University of New York, assignee. Curcumin analogues as zinc chelators and their uses"},{"key":"ref234","author":"Blair","year":"2024","journal-title":"inventors; Seattle Project Corp., assignee. Viral delivery of neoantigens"},{"key":"ref235","author":"Abudayyeh","year":"2024","journal-title":"inventors; Massachusetts Institute of Technology Broad Institute Inc., Harvard University, assignee. Systems, methods, and compositions for targeted nucleic acid editing"},{"key":"ref236","author":"Choi","year":"2024","journal-title":"inventors; Biontech US Inc., assignee. T cell receptor constructs and uses thereof"},{"key":"ref237","author":"Jessen","year":"2024","journal-title":"inventors; Velosbio Inc., assignee. ROR1 antibody immunoconjugates"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-10\/OncolRes-33-10-66624\/OncolRes-33-66624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:18:48Z","timestamp":1763345928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n10\/63885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":237,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.066624","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}